Peptide safety after surgery, what are we actually seeing side effect wise

I consult for a pro team and this comes up more than you'd think with guys rehabbing after surgery. Side effect wise the common stuff is mild, some site irritation, a headache here and there, nothing that's taken anyone off their program. The angiogenesis question is the one I actually take seriously though, it's biologically real even if nobody's published a case report tying it to a tumor.

The mechanism concern is legit. New vessel formation is how these peptides are proposed to speed healing, and it's also exactly how a pre-cancerous lesion could get fed if someone has one sitting undetected. There's no case report showing this actually happened in a human, and the animal safety data on BPC-157 is genuinely reassuring, no organ toxicity across a lot of preclinical work. There was a small Phase I human IV safety trial too that didn't flag anything major, but it was limited in scope, small numbers, short duration. So we're extrapolating from a pretty thin human dataset onto a population that's already stressed from surgery and often on other meds. That's the honest answer, not proven dangerous, not proven safe either.

Do we know the sample size on that Phase I trial? Limited scope is doing a lot of work in that sentence.

Small, and it was IV dosing specifically, not the sub-q protocols most people here are actually running.

My client had a mild headache week one, nothing after.

Some redness at the injection site for me, gone in a day or two.

When I went through my own post-op rehab I had a couple days of fatigue and a headache the first week, then nothing. Nowhere near what the surgery itself put me through.

For those of you with a cancer history or family history, has anyone actually gotten screened or gotten cleared before starting a peptide, or is that just not something people think about going in?

At my practice we require disclosure before combining anything peptide related with PT, not to gatekeep but because the blood thinner interaction gap is real, there's essentially zero published data on how BPC-157 or TB-500 behave alongside anticoagulants or antibiotics. Absence of reported problems isn't the same thing as proven safe, it just means nobody's looked. I'd rather have the surgeon and whoever's running the peptide protocol both know what the other has the patient on.

Never had one of my older clients report a real problem, mostly just mild stuff.

Worth naming too that post-surgical patients are often anxious and hypervigilant about their bodies, so normal recovery sensations sometimes get misattributed to whatever new thing they just started, peptide or otherwise. Doesn't mean the concerns here aren't valid, angiogenesis is a real conversation, but it's worth separating fear driven symptom scanning from an actual adverse reaction when you're talking someone through their first few weeks.

I see this with fascial stretch clients post-op fairly often, the complaints are almost always local injection irritation, rarely anything systemic.

Switching to sub-q killed the nausea for me completely.

This is helpful, going to make sure my patient loops her surgeon in before she starts anything.

Always loop the surgeon in, non negotiable with post-op patients.

Still think we need actual human trial data beyond one small Phase I before calling any of this settled, anecdotal reports aren't causal evidence.

Fair, appreciate everyone weighing in on this one.